Prognostic value of the 2026 AHA/ACC PE classification in ED patients with acute PE

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center prospective observational study will enroll 600 adults with confirmed acute pulmonary embolism from an Istanbul ED. Emergency clinicians will independently assign the 2026 AHA/ACC PE category (A–E) with an R modifier at presentation, and patients will be followed for 30 days to capture the composite outcome MAPEE (mortality, hemodynamic deterioration, or treatment escalation). No treatment will be altered by study participation; management will follow standard of care. The primary aim is to evaluate the prognostic value of the new classification for predicting MAPEE within 30 days. Data will describe the association between category assignment and adverse outcomes to inform risk stratification in acute PE.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age \>=18 years
2. Confirmed acute PE on CT pulmonary angiography (CTPA) within 24 hours of ED presentation
3. Informed consent obtained
4. Ability to complete 30-day follow-up

Exclusion Criteria:

1. Chronic thromboembolic pulmonary hypertension (CTEPH)
2. Age \<18 years
3. Pregnancy
4. Incomplete CTPA or non-diagnostic imaging
5. Prior PE within 3 months
6. Refusal of informed consent
7. Inability to complete 30-day follow-up (no phone/address)

Where it's running

• Marmara University Pendik Training and Research Hospital
  Istanbul, Turkey (Türkiye) Recruiting

Study contacts

• Principal investigator: Arzu Gundogdu — Marmara University
• Study coordinator: Emir Ünal, Assistant Professor
• Email: emirunal@gmail.com
• Phone: +90 216 657 06 06

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Aspiration thrombectomy with the Symphony or Prodigy devices

  This project will try the Symphony and Prodigy aspiration thrombectomy devices to remove arterial, venous, or pulmonary blood clots in adults.

  Recruiting at 13 sites Imperative Care, Inc. · Huntsville, Alabama and 12 other locations · NCT07350499

• Timing of anticoagulation for preventing blood clots in patients with brain hemorrhage

  This study is testing whether starting blood-thinning treatment early or later can help prevent blood clots in patients with bleeding in the brain while keeping them safe from more bleeding.

  Recruiting Pirogov Russian National Research Medical University · Moscow · NCT06753786

• Personalized blood thinner treatment for hip and knee replacement patients

  This study is testing if personalized blood thinner treatments can better prevent blood clots and bleeding in patients getting hip or knee replacements compared to standard treatments.

  Recruiting at 12 sites Phase 4 Leiden University Medical Center · Apeldoorn, Gelderland and 12 other locations · NCT06581965

• Evaluating a new decision support tool for diagnosing blood clots

  This study is testing a new tool to help doctors diagnose blood clots in patients who might have conditions like pulmonary embolism or deep vein thrombosis, using fresh blood samples.

  Recruiting at 4 sites Diagnostica Stago R&D · Niort, Sartres and 3 other locations · NCT06480994

• Using advanced imaging to predict the risk of blood clot recurrence in pulmonary embolism patients

  This study is testing if advanced imaging can help find out which patients with a history of pulmonary embolism are at risk for blood clots coming back, so they can get the right treatment.

  Recruiting at 11 sites University Hospital, Brest · Amiens, France and 12 other locations · NCT06372730

• Comparing rivaroxaban and low-molecular weight heparin for preventing blood clots in patients with lower limb trauma

  This study is testing if a new blood thinner called rivaroxaban can prevent blood clots better than a standard treatment in patients with leg injuries who are at high risk for clots.

  Recruiting at 26 sites Phase 3 University Hospital, Angers · Agen and 36 other locations · NCT06195540

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.